Daily notes / October 15, 2026

Fairmount filed a Schedule 13D reporting 19.99% of Alaunos Therapeutics

Written by a model from the facts OQRO holds and checked against them, sentence by sentence of October 15, 2026. Published October 17, 2026. 3 min read.

Tall office buildings around Trinity Church in lower Manhattan seen from above, with the church spire between the towers. — Skyscrapers around Trinity Church, New York, 1905. Photo: Detroit Publishing Company (scan by the New York Public Library), Public domain (scan of a 1905 photograph, New York Public Library Digital Collections). Original

The short answer

Fairmount Funds Management LLC filed a Schedule 13D on Oct 15, 2026, reporting 858,789 shares, 19.99% of Alaunos Therapeutics’ class. The filing records an ownership position, not when shares were bought. Other public records around the filing include company 8-K reports, another ownership disclosure, short-interest data and share-price context.

What did Fairmount report in the Schedule 13D?

The SEC Schedule 13D filed by Fairmount Funds Management LLC on Oct 15, 2026 reports 858,789 shares, 19.99% of the class of Alaunos Therapeutics (TCRT).

The filing reports an ownership position. A Schedule 13D is not a trade report and does not say when shares were bought.

What other ownership disclosures are on record?

Schedule 13D and 13G filings on Alaunos Therapeutics in the 180 days to Oct 15, 2026 also include Postma Robert W disclosing a 10.0% stake in TCRT. That filing was made on Oct 15, 2026.

The data provider lists Nov 12, 2026 as the next results date, 28 days after the filing date. Such dates can change.

What company filings came before the Schedule 13D?

Alaunos Therapeutics filed a Form 8-K on Oct 13, 2026, listing Items 1.01, 2.01, 3.02, 5.02, 5.03 and 7.01. OQRO classifies it as reporting a completed purchase or sale of a business or assets, a change to a top executive or board member, and 4 more items.

The company’s opening sentence reads: “Appointment of Directors In accordance with the Merger Agreement, on October 13, 2026, effective immediately after the effective time of the Second Merger, Peter Harwin was appointed to the Board as a director.”

On Oct 9, 2026, Alaunos filed a Form 8-K under Item 3.01, which OQRO classifies as reporting a notice from its stock exchange. The company’s opening sentence says it received notice from the Listing Qualifications Staff of The Nasdaq Stock Market LLC on April 9, 2026, stating that the company was not... The sentence in the pack ends there.

What else was reported around the filing date?

Alaunos filed a Form 8-K on Sep 22, 2026, listing Items 1.01 and 8.01. OQRO classifies it as reporting an important agreement and other company news.

Finnhub-listed coverage included “Alaunos Therapeutics Announces Acquisition of Velaris Therapeutics” (Yahoo, Oct 13, 2026), “Why is Alaunos Therapeutics Stock Trading 200% Higher on Tuesday?” (Benzinga, Oct 13, 2026), and “Paragon Labs Expands Leadership Team with Former Apogee Executives; Velaris Therapeutics Acquired by Alaunos Therapeutics, Inc.” (Yahoo, Oct 13, 2026.

TCRT closed at $3.03 on Oct 13, 2026, the last session on or before the filing date. From Sep 14, 2026 to Oct 13, 2026, the close moved from $1.49 to $3.03, a change of +103.4%. FINRA short interest for TCRT on the settlement date of Sep 30, 2026 was 9,736 shares, +60.26% on the previous report, about 1 days of average volume.

What this does not tell you?

The Schedule 13D does not say when shares were bought. An 8-K item says what the company reported, not what it means for the share price. The filing does not explain share-price moves, and other news can move a price.

Price moves are context only. The headlines are listed as published by the outlets; OQRO has not checked them and does not summarize the articles. The results date can change. This describes public filings and is not investment advice. See Alaunos Therapeutics on OQRO.

Sources

A model wrote this page from the facts OQRO holds; every number, date, name and link in it was checked against those facts before publication, and a text that failed the check was not published. It describes what was filed, not why, and it is not investment advice. How OQRO treats data